秒速时时彩

NBP Pharmaceutical won the honor of "Single Champion Manufacturing Demonstration Enterprise"

Posted: November 27, 2019 Posted by: CSPC


According to the "Implementation of Special Actions for the Cultivation and Promotion of Single Champion Enterprises in Manufacturing Industry" (Ministry of Industry and Information Technology (2016) No. 105), after the enterprise's self-declaration, the recommendation of the local industry and informatization authorities and central enterprises, the qualifications of industry associations, the expert group For demonstration and online publicity, the Ministry of Industry and Information Technology of the People's Republic of China identified the fourth batch of individual champions (products) in manufacturing. CSPC Enbipu Pharmaceutical Co., Ltd. won the honor of "Single Champion Model Enterprise in Manufacturing".


WeChat screenshot_20191127141841.png


The purpose of organizing the selection of the fourth batch of individual championships in the manufacturing industry is to accelerate the cultivation of vanguard enterprises with innovative capabilities and world-class enterprises with global competitiveness, to enhance the innovation and professionalism and internationalization of manufacturing enterprises, and to promote manufacturing. High-quality development of the industry.

On December 18, 2018, at the Ministry of Industry and Information Technology and China Industrial and Economic Federation's Manufacturing Championship Single Champion Experience Exchange Meeting, Wang Jiangping, a member of the Party Leadership Group and Deputy Minister of the Ministry of Industry and Information Technology, pointed out that the current single champion enterprises in China are Various industries have played a good role in demonstration, and the company's consciousness of "sharpening a sword in ten years" has been strengthened, and the characteristics of the industry's vanguard have become more prominent: the technological innovation capability has continued to increase, and the average research and development intensity is 5 Times, the number of valid patents and invention patents far exceeds the level of general manufacturing companies; the global market leadership has been further consolidated, and some companies have far-reaching market shares; strengthened cooperation with upstream and downstream companies to lead the overall improvement of the industrial chain; and the quality and benefits of enterprise development have become more prominent The industry distribution has been gradually optimized, and more champions have gradually emerged in the advanced manufacturing and emerging industries.


Plant area of CSPC Enbipu_copy.jpg


CSPC Enbipu Pharmaceutical Co., Ltd. is a modern pharmaceutical company mainly producing innovative drugs. The company's heavy product is Enbipu (chemical name: butylphthalide), which is one of the representatives of CSPC's new drug research and development achievements. , Is China's third national class I new drug with independent intellectual property rights, and a global leading drug in the field of stroke treatment. Since its listing, more than 10 million stroke patients have been cured or alleviated.

During the selection of individual champions in the manufacturing industry, it advocates professional and high-quality development. CSPC has long been committed to improving the scientific and technological level of the cardiovascular and cerebrovascular field in China, and has focused on the cardio-cerebral-vascular series. It is determined to gradually build the entire process of the cardiovascular and cerebrovascular Protect the product chain. In 2019, CSPC's clopidogrel (Encun®), ticagrelor (merlotin®), and tirofiban (colan®) have been listed on the market, marking CSPC's Product lines in the vascular field are becoming more abundant.